摘要：THE IDENTIFICATION OF WOMEN HAVING OR BEING ABLE TO DEVELOP CERVICAL CANCER IS A MAJOR CONCERN WORLDWIDE EXPRESSED BY ENDEAVORS TO IMPLEMENT NEW METHODS OF SCREENING AND TRIAGE FOR PRECANCEROUS CERVICAL LESIONS (PCL). THE PRESENT WORK ENCOMPASSES RESULTS OF MANY TRIALS AND OBSERVATIONAL STUDIES PUBLISHED ON INTERNATIONAL DATABASES DURING LAST 10 YEARS. THE PURPOSE OF CURRENT STUDY IS TO HIGHLIGHT THE FEATURES OF ADVANCED BIOTECHNOLOGIES, CONCERNING THEIR CAPACITY OF LEADING TO AN EARLY RIGHT DIAGNOSIS SUPPORTING, TO COMPARE THE EFICACITY OF THESE TESTS SUCH SENSITIVITY AS SPECIFICITY, TO TRIAGE BETWEEN REGRESSIVE AND PROGRESSIVE PCL, TO HIGHLIGHT THE DIFFERENCE CONCERNING SCREENING METHODS ADOPTED BY THE NATIONAL PROGRAMMES WORLDWIDE. THE RESULTS SHOWED THAT PAP TEST IS AN EXPENSIVE METHOD, WITH HIGH LEVEL OF SUBJECTIVE ASSESSMENT AND WITHOUT POSSIBILITY OF DISCRIMINATION BETWEEN DIFERENT KINDS OF CYTOLOGIES. HUMAN PAPILLOMAVIRUS (HPV) GENOTYPE ALONE DOESN’T ALLOW TO DISTINGUISH TRANSIENT VERSUS PROGRESSIVE HPV INFECTION. IMMUNOSTAINING CYCLINE P16INK4A AND THE MORE PERFORMANT TEST, DUAL TEST P16INK4A/ KI 67 ALLOW THE TRIAGE OF CASES ABLE TO DEVELOP CANCER USED ALONE OR AS CO-TEST TO PRIMARY HPV SCREENING. PRIMARY CERVICAL SCREENING WITH HPV GENOTYPE ASSOCIATE WITH ONE OF CO-CIYTOLOGIC TEST IMPROVE THE ACCURACY OF AN EARLY DIAGNOSIS.
关键词：CERVICAL CANCER;PRECANCEROUS CERVICAL LESIONS;BIOTECHNOLOGIES;PAP TEST;HPV GENOTYPE;P16INK4A;P16INK4A/ KI 67
